NO20041012L - Syntese av enantiomeriske rene amino-substituerte kodenserte bisykliske ringer - Google Patents

Syntese av enantiomeriske rene amino-substituerte kodenserte bisykliske ringer

Info

Publication number
NO20041012L
NO20041012L NO20041012A NO20041012A NO20041012L NO 20041012 L NO20041012 L NO 20041012L NO 20041012 A NO20041012 A NO 20041012A NO 20041012 A NO20041012 A NO 20041012A NO 20041012 L NO20041012 L NO 20041012L
Authority
NO
Norway
Prior art keywords
amino
fused bicyclic
substituted fused
synthesis
substituted
Prior art date
Application number
NO20041012A
Other languages
English (en)
Norwegian (no)
Inventor
Ernest J Mceachern
Krystyna A Skupinska
Renato T Skerlj
Gary J Bridger
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of NO20041012L publication Critical patent/NO20041012L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Quinoline Compounds (AREA)
NO20041012A 2001-09-12 2004-03-10 Syntese av enantiomeriske rene amino-substituerte kodenserte bisykliske ringer NO20041012L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32320101P 2001-09-12 2001-09-12
PCT/US2002/029372 WO2003022785A2 (en) 2001-09-12 2002-09-12 Synthesis of enantiomerically pure amino-substituted fused bicyclic rings

Publications (1)

Publication Number Publication Date
NO20041012L true NO20041012L (no) 2004-03-10

Family

ID=23258145

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041012A NO20041012L (no) 2001-09-12 2004-03-10 Syntese av enantiomeriske rene amino-substituerte kodenserte bisykliske ringer

Country Status (18)

Country Link
US (3) US6825351B2 (de)
EP (1) EP1487795B1 (de)
JP (1) JP4431389B2 (de)
KR (1) KR20040044909A (de)
CN (3) CN101353324A (de)
AT (1) ATE486850T1 (de)
BR (1) BR0212443A (de)
CA (1) CA2456614A1 (de)
DE (1) DE60238218D1 (de)
HU (1) HUP0600777A2 (de)
IL (2) IL160115A0 (de)
MX (1) MXPA04002356A (de)
NO (1) NO20041012L (de)
NZ (1) NZ531482A (de)
PL (1) PL372705A1 (de)
RU (1) RU2308451C2 (de)
WO (1) WO2003022785A2 (de)
ZA (1) ZA200400750B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2006052514A1 (en) * 2004-11-04 2006-05-18 Merck & Co., Inc. Asymmetric hydrogenation of enamides
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
CA2624138A1 (en) * 2005-09-29 2007-04-05 British Columbia Cancer Agency Branch Method and composition for increasing the engraftment efficiency of stem cells
US20080155015A1 (en) * 2006-12-20 2008-06-26 Omx Technology Ab Intelligent information dissemination
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110105798A1 (en) * 2008-06-27 2011-05-05 O'shea Paul Synthesis of chiral amines
KR20100032496A (ko) * 2008-09-18 2010-03-26 주식회사 이큐스팜 신규 5-(4-아미노페닐)-이소퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
HRP20210334T1 (hr) 2009-12-11 2021-04-02 Medregen, Llc Metode liječenja u kojima se primjenjuju mobilizatori matičnih stanica i imunosupresivna sredstva
EP2549992B1 (de) 2010-03-23 2019-08-14 The Johns Hopkins University Behandlungsverfahren mithilfe von stammzellenmobilisatoren
CN102911996B (zh) * 2011-10-26 2014-04-23 苏州同力生物医药有限公司 一种左旋吡喹酮的制备方法
FR2993561B1 (fr) * 2012-07-17 2014-10-31 Servier Lab Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels
EP3030232B1 (de) 2013-04-29 2022-07-06 Medregen, LLC Wundheilung durch mobilisierung von autologen stammzellen
US9440899B2 (en) 2014-12-15 2016-09-13 Rohm And Haas Electronic Materials Llc Purification method
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
HUE060517T2 (hu) 2015-12-22 2023-03-28 X4 Pharmaceuticals Inc Immunhiányos betegség kezelésére szolgáló eljárások
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
US20190194122A1 (en) * 2017-12-27 2019-06-27 Apotex Inc. Processes for the Preparation of Dasotraline and Intermediates Thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
MX2021008824A (es) 2019-01-23 2021-10-13 Univ Johns Hopkins Análogos no inmunosupresores de tacrolimus (fk506) y uso de los mismos.
US20230022146A1 (en) 2019-06-17 2023-01-26 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス4 ファーマシューティカルズ, インコーポレイテッド 好中球減少症を処置する方法
CA3205138A1 (en) 2020-12-17 2022-06-23 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
CN115872820B (zh) * 2021-09-28 2024-08-06 中国科学院大连化学物理研究所 仿生催化不对称氢化合成手性2-官能团化四氢喹啉的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA321A (en) 1870-03-29 C.A. Gregory Improvements on apparatus for filling bottles, vials and other vessels and gauging their contents
DE1207930B (de) * 1956-02-03 1965-12-30 Basf Ag Verfahren zur Herstellung von Pyridin- bzw. Tetrahydrochinolinderivaten
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9200245D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
NZ331875A (en) 1996-03-22 2000-01-28 Du Pont Pharm Co Asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs
GB9726229D0 (en) 1997-12-12 1998-02-11 Zeneca Ltd Resolution of chiral amines
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
AP1654A (en) * 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.

Also Published As

Publication number Publication date
US20030114679A1 (en) 2003-06-19
JP2005508316A (ja) 2005-03-31
US20050080267A1 (en) 2005-04-14
EP1487795A2 (de) 2004-12-22
CN1817864A (zh) 2006-08-16
PL372705A1 (en) 2005-07-25
EP1487795B1 (de) 2010-11-03
HUP0600777A2 (en) 2007-01-29
DE60238218D1 (de) 2010-12-16
MXPA04002356A (es) 2004-06-29
HK1074044A1 (en) 2005-10-28
CN101353324A (zh) 2009-01-28
CA2456614A1 (en) 2003-03-20
NZ531482A (en) 2007-04-27
BR0212443A (pt) 2005-03-15
RU2004110928A (ru) 2005-10-10
JP4431389B2 (ja) 2010-03-10
WO2003022785A3 (en) 2004-09-30
US7452994B2 (en) 2008-11-18
EP1487795A4 (de) 2005-02-09
IL160115A (en) 2010-12-30
KR20040044909A (ko) 2004-05-31
US6825351B2 (en) 2004-11-30
WO2003022785A2 (en) 2003-03-20
CN100412062C (zh) 2008-08-20
IL160115A0 (en) 2004-06-20
CN1608052A (zh) 2005-04-20
RU2308451C2 (ru) 2007-10-20
US20070060757A1 (en) 2007-03-15
US7135570B2 (en) 2006-11-14
ZA200400750B (en) 2005-04-06
CN1272322C (zh) 2006-08-30
ATE486850T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
IL160115A0 (en) Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
NZ765535A (en) Enantiomeric separation of racemic nicotine by addition of an o,o’-disubstituted tartaric acid enantiomer
DE60042035D1 (de) Verfahren und zusammensetzungen zur herstellung von ophtalmischen linsen
DE60202958D1 (de) Stabiles polymorph von flibanserin, industrielles verfahren zu dessen herstellung und dessen verwendung zur herstellung von medikamenten
Khatik et al. Stereoselective synthesis of (S)-dapoxetine: a chiral auxiliary mediated approach
EA200400487A1 (ru) Фармацевтическая композиция длительного высвобождения, содержащая метформин
ATE306315T1 (de) Verfahren zur herstellung blauer mikrokapseln
DE69404306D1 (de) Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine
DE50115655D1 (de) Verfahren zur herstellung von unsymmetrischen 4,6-bis(aryloxy)pyrimidin-derivaten
BRPI0410619A (pt) processo para a produção de um flange de conexão anular, e, flange de conexão anular
ATE291006T1 (de) Verfahren zur herstellung von salbutamolisomeren
AR030938A1 (es) Proceso de obtencion de los enantiomeros de la cetamina racemica; proceso de obtencion de sales farmaceuticamente aceptables de enantiomeros de la cetamina racemica y utilizacion de las sales farmaceuticamente aceptables obtenidas por el referido proceso
ATE414781T1 (de) Verbessertes verfahren zur herstellung des coenzyms q-10
HUP9802146A2 (hu) Eljárás optikailag aktív 2-amino-omega-oxoalkánsav-származékok előállítására és a vegyületek
RU2007138100A (ru) Дипиразолы в качестве средств для центральной нервной системы
ATE301127T1 (de) Ferrocenylliganden und ein verfahren zur herstellung solcher liganden
ATE496038T1 (de) Verfahren zur herstellung von quetiapin
DE60003807D1 (de) Enantiomere von mercaptolactonen und verfahren zu ihrer herstellung
HUP0002661A2 (hu) Eljárás enantiomerekben gazdag N-derivatizált laktámok előállítására
Coldham et al. Chiral organolithium species: determination of the rate of cyclization and extent of racemization
DE602004015310D1 (de) Verfahren zur herstellung von mycophenolatmofetil
DE60303825D1 (de) Verfahren zur herstellung von enantiomeren von indol-2,3-dion-3-oximderivaten
ATE360006T1 (de) Verfahren zur racematspaltung von nefopam
PT946537E (pt) Processo para a producao estereosselectiva de compostos de nitro-enamina
NO20033944D0 (no) Ny assymetrisk fremgangsmåte for fremstilling av diarylmetylpiperazinderivater og nye assymetriske diarylmetylaminer som mellomprodukter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application